Validation of the anti-tumor effectiveness of both miR-423-5p replacement and MALAT-1 downregulation through LNA Antisense GapmeR delivery was assessed in an in vivo model of HCC. The gene discussed is MALAT1; the disease is hepatocellular carcinoma.